MCID: THY107
MIFTS: 42

Thymoma, Familial

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymoma, Familial

MalaCards integrated aliases for Thymoma, Familial:

Name: Thymoma, Familial 57 70
Thymoma 58 70
Primary Thymic Epithelial Neoplasm 58
Primary Thymic Epithelial Tumor 58
Thymic Neoplasia 57
Thymus Neoplasms 70

Characteristics:

Orphanet epidemiological data:

58
thymoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
somatic mutation


HPO:

31
thymoma, familial:
Inheritance autosomal recessive inheritance somatic mutation


Classifications:



External Ids:

OMIM® 57 274230
MESH via Orphanet 45 D013945
ICD10 via Orphanet 33 D15.0 D38.4
UMLS via Orphanet 71 C0040100
Orphanet 58 ORPHA99867
MedGen 41 C1848814
UMLS 70 C0040100 C1848814 C3714644

Summaries for Thymoma, Familial

OMIM® : 57 Thymomas are low-grade epithelial cancers of the thymus. Familial occurrence of thymoma is rare. (274230) (Updated 20-May-2021)

MalaCards based summary : Thymoma, Familial, also known as thymoma, is related to good syndrome and type c thymoma. The drugs Antimitotic Agents and Tubulin Modulators have been mentioned in the context of this disorder. Affiliated tissues include thymus, thyroid and t cells, and related phenotypes are ptosis and diplopia

Related Diseases for Thymoma, Familial

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 669)
# Related Disease Score Top Affiliating Genes
1 good syndrome 11.5
2 type c thymoma 11.4
3 cortical thymoma 11.3
4 predominantly cortical thymoma 11.3
5 epithelial malignant thymoma 11.3
6 invasive malignant thymoma 11.2
7 mixed type thymoma 11.2
8 dendritic cell thymoma 11.2
9 encapsulated thymoma 11.2
10 thymoma type ab 11.1
11 combined thymoma 11.1
12 malignant type ab thymoma 11.1
13 noninvasive malignant thymoma 11.1
14 malignant type a thymoma 11.1
15 thymoma type a 11.1
16 thymoma type b 11.1
17 thymus cancer 11.0
18 thymic epithelial tumor 10.9
19 acquired pure red cell aplasia 10.9
20 morvan's fibrillary chorea 10.9
21 limbic encephalitis with lgi1 antibodies 10.9
22 pure red-cell aplasia 10.7
23 virus-associated trichodysplasia spinulosa 10.5
24 polymyositis 10.5
25 rare tumor 10.5
26 autoimmune disease 10.4
27 paraneoplastic syndromes 10.4
28 encephalitis 10.4
29 aplastic anemia 10.4
30 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.4
31 myositis 10.4
32 ptosis 10.4
33 myocarditis 10.4
34 immune deficiency disease 10.4
35 candidiasis 10.4
36 nephrotic syndrome 10.4
37 systemic lupus erythematosus 10.4
38 lichen planus 10.4
39 deficiency anemia 10.3
40 limbic encephalitis 10.3
41 thyroiditis 10.3
42 lupus erythematosus 10.3
43 thymic epithelial neoplasm 10.3
44 respiratory failure 10.3
45 neutropenia 10.3
46 lymphoma 10.3
47 hemopericardium 10.3
48 pericardial effusion 10.3
49 thymoma 10.3
50 graft-versus-host disease 10.3

Graphical network of the top 20 diseases related to Thymoma, Familial:



Diseases related to Thymoma, Familial

Symptoms & Phenotypes for Thymoma, Familial

Human phenotypes related to Thymoma, Familial:

58 31 (show all 33)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ptosis 58 Frequent (79-30%)
2 diplopia 58 Frequent (79-30%)
3 dysphagia 58 Frequent (79-30%)
4 respiratory insufficiency 31 HP:0002093
5 arthritis 58 Occasional (29-5%)
6 fatigue 58 Frequent (79-30%)
7 abnormality of the pleura 58 Occasional (29-5%)
8 alopecia 58 Occasional (29-5%)
9 thyroiditis 58 Occasional (29-5%)
10 decreased antibody level in blood 58 Occasional (29-5%)
11 hemolytic anemia 58 Occasional (29-5%)
12 nephrotic syndrome 58 Occasional (29-5%)
13 dyspnea 58 Frequent (79-30%)
14 neoplasm 31 HP:0002664
15 cough 58 Frequent (79-30%)
16 pericarditis 58 Occasional (29-5%)
17 myocarditis 58 Occasional (29-5%)
18 chest pain 58 Frequent (79-30%)
19 skin rash 58 Occasional (29-5%)
20 limitation of joint mobility 58 Occasional (29-5%)
21 keratoconjunctivitis sicca 58 Occasional (29-5%)
22 abnormality of the peritoneum 58 Occasional (29-5%)
23 lymphadenopathy 58 Frequent (79-30%)
24 neoplasm of the thymus 58 Very frequent (99-80%)
25 pancytopenia 58 Occasional (29-5%)
26 interstitial pulmonary abnormality 58 Frequent (79-30%)
27 myositis 58 Occasional (29-5%)
28 xerostomia 58 Occasional (29-5%)
29 abnormality of the mediastinum 58 Very frequent (99-80%)
30 fatigable weakness 58 Frequent (79-30%)
31 abnormality of lymphocytes 58 Very frequent (99-80%)
32 thymoma 31 HP:0100522
33 b lymphocytopenia 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Respiratory:
respiratory insufficiency

Neoplasia:
thymoma

Immunology:
thymoma

Clinical features from OMIM®:

274230 (Updated 20-May-2021)

Drugs & Therapeutics for Thymoma, Familial

Drugs for Thymoma, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antimitotic Agents Phase 4
2 Tubulin Modulators Phase 4
3
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
5
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
6
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
10 Methylprednisolone Acetate Phase 3
11 Etoposide phosphate Phase 3
12
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
13
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
14
Pasireotide Approved Phase 2 396091-73-9 9941444
15
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
16
Melphalan Approved Phase 2 148-82-3 4053 460612
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Busulfan Approved, Investigational Phase 2 55-98-1 2478
20
ramucirumab Approved, Investigational Phase 2 947687-13-0
21
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
22
Nedaplatin Approved, Investigational Phase 2 95734-82-0
23
nivolumab Approved Phase 2 946414-94-4
24
Plicamycin Approved, Investigational, Withdrawn Phase 1, Phase 2 18378-89-7 163659 163660 163661 163662 163663 163664
25
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
26
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
27
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
28
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
29
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
30
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
31
Pembrolizumab Approved Phase 2 1374853-91-4
32
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
33
Povidone Approved Phase 1, Phase 2 9003-39-8 131751496
34
Povidone-iodine Approved Phase 1, Phase 2 25655-41-8
35
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
36
Lenvatinib Approved, Investigational Phase 2 417716-92-8
37
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
38
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
39
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
40
Belinostat Approved, Investigational Phase 1, Phase 2 866323-14-0
41
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
42
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
43
Doxepin Approved, Investigational Phase 2 1668-19-5 667477 667468
44
Promethazine Approved, Investigational Phase 2 60-87-7 4927
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
46
Amrubicin Investigational Phase 2 110267-81-7
47
Lexatumumab Investigational Phase 2 845816-02-6
48
Molgramostim Investigational Phase 2 99283-10-0
49
Cadexomer iodine Experimental Phase 1, Phase 2 94820-09-4
50
Saracatinib Investigational Phase 2 379231-04-6

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Single-Arm Study to Carbo-paclitaxel/ Nab-paclitaxel Combined With Pembrolizumab as the First Line Therapy in Treating Patients With Locally Advanced or Metastatic Invasive Thymoma and Thymic Carcinoma That Cannot Be Removed by Surgery Recruiting NCT04554524 Phase 4 Chemotherapy+Pembrolizumab.
2 A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone Completed NCT00294658 Phase 3 prednisone alone
3 An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
4 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
5 A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
6 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Unknown status NCT03449173 Phase 2 Sunitinib
7 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Unknown status NCT03466827 Phase 2 Selinexor
8 Samsung Medical Center Unknown status NCT03219554 Phase 2 Palbociclib
9 Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size Completed NCT00332969 Phase 2 Octreotide
10 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
11 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
12 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
13 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
14 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
15 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
16 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
17 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Completed NCT02049047 Phase 2 Everolimus
18 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
19 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
20 A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin Completed NCT02420691 Phase 2 Ribociclib
21 Radiofrequency Ablation of Pulmonary Malignancy Completed NCT00024076 Phase 2
22 A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy Completed NCT02607631 Phase 2 Pembrolizumab
23 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
24 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
25 Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies Completed NCT01163552 Phase 2
26 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
27 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
28 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2
29 A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Recruiting NCT04417660 Phase 2 M7824
30 A Prospective, Phase Ⅱ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
31 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
32 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
33 A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT) Recruiting NCT03193437 Phase 2 Open Label Selinexor
34 Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
35 A Phase II, Neo-adjuvant Pembrolizumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Pembrolizumab Consolidation Therapy in Locally Advanced Thymic Epithelial Tumor (TET) Recruiting NCT03858582 Phase 2 pembrolizumab
36 A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
37 A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma Recruiting NCT04469725 Phase 2 KN046
38 An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Recruiting NCT04321330 Phase 2 Atezolizumab
39 A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma Recruiting NCT03463460 Phase 2 Sunitinib Malate
40 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
41 A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy Active, not recruiting NCT01621568 Phase 2 Sunitinib
42 A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007) Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
43 Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
44 An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Active, not recruiting NCT02307500 Phase 2 Regorafenib
45 Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Active, not recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
46 Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors Not yet recruiting NCT04517539 Phase 2 rhGM-CSF,Peginterferon alfa-b2,radiation
47 Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor Not yet recruiting NCT04667793 Phase 2 Toripalimab;Chemotherapy;Chemotherapy
48 The Study of Extended Thymectomy and Pleural Reductive Surgery (PRS) With Povidone-iodine Pleural Lavage in Patients With Stage IVA Thymic Malignancies Not yet recruiting NCT04371458 Phase 1, Phase 2 Intraoperative providone-iodine lavage
49 A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI. Not yet recruiting NCT04710628 Phase 2 Pembrolizumab;Lenvatinib 10 mg
50 A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Suspended NCT02220855 Phase 2 BKM120

Search NIH Clinical Center for Thymoma, Familial

Genetic Tests for Thymoma, Familial

Anatomical Context for Thymoma, Familial

MalaCards organs/tissues related to Thymoma, Familial:

40
Thymus, Thyroid, T Cells, Bone Marrow, Lung, B Cells, Brain

Publications for Thymoma, Familial

Articles related to Thymoma, Familial:

(show top 50) (show all 8241)
# Title Authors PMID Year
1
Familial occurrence of thymoma and autoimmune diseases with the constitutional translocation t(14;20)(q24.1;p12.3). 57 61
15942943 2005
2
Thymic neoplasia in two male siblings. 57 61
7121071 1982
3
Familial occurrence of thymoma. 57 61
4683164 1973
4
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 57
24974848 2014
5
PATHOLOGY AND CLINICAL BEHAVIOR OF THYMOMAS. A SURVEY OF 51 CASES. 57
14332543 1965
6
Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients. 61
33578311 2021
7
Risk factors for developing post-thymectomy myasthenia gravis in patients with thymoma. 61
33434360 2021
8
Management of thymomatous myasthenia gravis - Case report of a rare Covid19 infection sequelae. 61
33744800 2021
9
Prognostic Factor of Completely Resected and Pathologic T3 N0 M0 Thymic Epithelial Tumor. 61
32888924 2021
10
Good's syndrome with a relapsed bloodstream infection induced by Alcaligenes sp. after thymectomy: A case report. 61
33680121 2021
11
Meta-Analysis of Limited Thymectomy versus Total Thymectomy for Masaoka Stage I and II Thymoma. 61
33767014 2021
12
Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021? 61
33781440 2021
13
Commentary: Progress, or just movement, on thymoma staging? 61
33293061 2021
14
Surgical feasibility and long-term outcome of superior vena cava replacement for advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy. 61
33569912 2021
15
Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients. 61
33515812 2021
16
Dural venous sinus tumour thrombus from metastatic thymoma. 61
33775340 2021
17
Thymoma pathology and myasthenia gravis outcomes. 61
33675078 2021
18
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis. 61
33547763 2021
19
Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. 61
33721382 2021
20
Pyoderma gangrenosum with thymoma and myasthenia gravis: A case report. 61
32920928 2021
21
Immunodeficiency and Thymoma: A Case Report on Good Syndrome, a Diagnosis Frequently Missed and Forgotten. 61
33712551 2021
22
Immunodeficiency and thymoma in Good syndrome: Two sides of the same coin. 61
33418010 2021
23
The Anti-Melanogenesis Effect of 3,4-Dihydroxybenzalacetone through Downregulation of Melanosome Maturation and Transportation in B16F10 and Human Epidermal Melanocytes. 61
33802228 2021
24
Two Cases of anti-PIT-1 Hypophysitis Exhibited as a Form of Paraneoplastic Syndrome not Associated With Thymoma. 61
33506159 2021
25
Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. 61
33801977 2021
26
Video-assisted thoracoscopic surgery is safe and reliable for large and invasive primary mediastinal tumors. 61
33786130 2021
27
Prosthetic Reconstruction of Superior Vena Cava System for Thymic Tumor: A Retrospective Analysis of 22 Cases. 61
32005044 2021
28
Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol. 61
33485878 2021
29
Thymic Epithelial Neoplasms: Tumor-Node-Metastasis Staging. 61
33551080 2021
30
Granulomatous-lymphocytic Interstitial Lung Disease Associated with Good's Syndrome that Responded to Immunoglobulin Therapy. 61
33716283 2021
31
Surgical management of thymic epithelial tumors. 61
32647929 2021
32
Identification of differentially expressed circular RNAs associated with thymoma. 61
33704915 2021
33
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. 61
33723724 2021
34
Thymoma with a feeding vessel from coincident coronary-pulmonary artery fistulas. 61
33691537 2021
35
Histopathological heterogeneity in an atypical type A thymoma variant with pulmonary metastases. 61
33657271 2021
36
Comparison of Subxiphoid and Intercostal Uniportal Thoracoscopic Thymectomy for Nonmyasthenic Early-Stage Thymoma: A Retrospective Single-Center Propensity-Score Matching Analysis. 61
32886931 2021
37
A RARE CASE OF MEDIASTINAL MASSON'S TUMOR MIMICKING A THYMOMA. 61
33794162 2021
38
Micronodular Thymoma With Lymphoid Stroma: A Trio of Cases, With Diverse-associated Histological Features. 61
33683925 2021
39
Caspr2 autoantibody-associated Morvan syndrome predating thymoma relapse by 30 months. 61
33485137 2021
40
Erratum to: Comparison of Subxiphoid and Intercostal Uniportal Thoracoscopic Thymectomy for Nonmyasthenic Early-Stage Thymoma: A Retrospective Single-Center Propensity-Score Matching Analysis. 61
33626591 2021
41
Thymoma in an aged backyard Leghorn chicken, with reviews of a database and literature. 61
33525992 2021
42
18F-Fluciclovine Uptake in Thymoma Demonstrated on PET/MRI. 61
32956127 2021
43
Intensity Modulated Radiation Therapy for Pleural Recurrence of Thymoma: A Prospective Phase 2 Study. 61
33039590 2021
44
Ectopic thymoma in the middle mediastinum: A case report and literature review. 61
33763676 2021
45
Which Is the Best Treatment in Recurrent Thymoma? A Systematic Review and Meta-Analysis. 61
33805310 2021
46
Thymic Epithelial Neoplasms: Radiologic-Pathologic Correlation. 61
33551079 2021
47
Different View on Tumor Size Dilemma in Tumor-Node-Metastasis Staging System for Thymoma. 61
32898892 2021
48
A Pregnant Patient With a Large Anterior Mediastinal Mass for Thymectomy Requiring One-Lung Anesthesia. 61
33222654 2021
49
The Duke myasthenia gravis clinic registry: I. Description and demographics. 61
33205437 2021
50
Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic. 61
33544334 2021

Variations for Thymoma, Familial

Expression for Thymoma, Familial

Search GEO for disease gene expression data for Thymoma, Familial.

Pathways for Thymoma, Familial

GO Terms for Thymoma, Familial

Sources for Thymoma, Familial

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....